Last reviewed · How we verify
NCT03699345
CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System
trial testing Transcatheter Aortic Valve Replacement (TAVR) in Aortic Valve Stenosis in 87 participants. Completed in 20 August 2024.
14 August 2019
Quick facts
| Lead sponsor | Edwards Lifesciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 87 |
| Start date | 7 January 2019 |
| Primary completion | 14 August 2019 |
| Estimated completion | 20 August 2024 |
| Sites | 11 locations across Denmark, France, Netherlands, United Kingdom, Germany, Spain |
Drugs / interventions tested
- Transcatheter Aortic Valve Replacement (TAVR)
Conditions studied
- Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
Sponsor
Edwards Lifesciences — full company profile →
Who can join
Eligibility, any sex, with Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will monitor device performance and safety of the Edwards CENTERA Transcatheter Heart Valve (THV) system in patients with severe, symptomatic aortic valve stenosis who are indicated for aortic valve replacement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03699345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcatheter Aortic Valve Replacement (TAVR)
Trials testing the same drug.
- NCT06830499 — Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China · recruiting
- NCT06295068 — Evaluation of ARi With OpSens SavvyWire · terminated
- NCT03130491 — European Study Evaluating the EMBLOK Embolic Protection System During TAVR · NA · completed
Other recruiting trials for Aortic Valve Stenosis
Currently open trials in the same condition.
- NCT07455292 — Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging · NA · recruiting
- NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
- NCT07145463 — Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aorti · NA · recruiting
- NCT07520656 — Impact of Transcatheter Aortic Valve Implantation and Mitral Valve Repair on Sleep-Disordered Breathing · recruiting
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
Other Edwards Lifesciences trials
Trials by the same sponsor.
- NCT07317648 — ClearSight NextGen1 Study · NA · completed
- NCT06833476 — TTVR STRONG Under Coverage With Evidence Development (CED) Study · recruiting
- NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
- NCT06834516 — ClearSight Baby Cuff · completed
- NCT05957406 — SMART TRENDS Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03699345 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Edwards Lifesciences
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03699345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing